<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33851875</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8395</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Expert review of vaccines</Title><ISOAbbreviation>Expert Rev Vaccines</ISOAbbreviation></Journal><ArticleTitle>Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies.</ArticleTitle><Pagination><StartPage>365</StartPage><EndPage>373</EndPage><MedlinePgn>365-373</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14760584.2021.1903879</ELocationID><Abstract><AbstractText Label="INTRODUCTION">As the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to spread, several variants have emerged. Variants B.1.1.7 and B.1.351 have attracted significant attention owing to their widespread transmission and possible immune evasion. A total of 19 SARS-CoV-2 vaccines based on original strains have entered clinical studies, including nine vaccines that have obtained emergency use or conditional marketing authorizations. However, newly emerging variants may affect their protective efficacy. Decreased efficacy of the Novartis, Johnson &amp; Johnson, and AstraZeneca vaccines against B.1.351 has been reported. The spread of variants creates a tremendous challenge for the prevention and control of the SARS-CoV-2 pandemic via vaccination. Several response strategies, including accelerating massive rollouts of current vaccines, increasing vaccine immunogenicity by increasing vaccination doses, and accelerating next-generation vaccines against variants, have been suggested.</AbstractText><AbstractText Label="AREAS COVERED">SARS-CoV-2 vaccine efficacy against variants and response strategies for emerging variants.</AbstractText><AbstractText Label="EXPERT OPINION">Current SARS-CoV-2 vaccines authorized for emergency use or under clinical trials have shown certain advantages in providing adequate protection against new variants. We analyzed the effects of reported variants on neutralizing antibodies and the protective efficacy of different vaccines and propose strategies for applying current vaccines against variants and developing next-generation vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Lianlian</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jialu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Miao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Vaccines</MedlineTA><NlmUniqueID>101155475</NlmUniqueID><ISSNLinking>1476-0584</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093522" MajorTopicYN="N">COVID-19 Serotherapy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-cov-2</Keyword><Keyword MajorTopicYN="N">neutralization</Keyword><Keyword MajorTopicYN="N">protective efficacy</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword><Keyword MajorTopicYN="N">variant</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>14</Day><Hour>12</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33851875</ArticleId><ArticleId IdType="pmc">PMC8054487</ArticleId><ArticleId IdType="doi">10.1080/14760584.2021.1903879</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang JW, Tambyah PA, Hui DS.. Emergence of a new SARS-CoV-2 variant in the UK. J Infect. 2020;S0163-4453(20):30786&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834693</ArticleId><ArticleId IdType="pubmed">33383088</ArticleId></ArticleIdList></Reference><Reference><Citation>Volz E, Hill V, Mccrone JT, et al. Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. Cell. 2021;184(1):64&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674007</ArticleId><ArticleId IdType="pubmed">33275900</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans C. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182(4):812&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7332439</ArticleId><ArticleId IdType="pubmed">32697968</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambaut A, Loman N, Pybus O, et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations 2020 [cited
2021. 
February
15]. Available from: https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563</Citation></Reference><Reference><Citation>Tegally H, Wilkinson E, Giovanetti M, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. Nature. 2021.DOI:10.1038/s41586-021-03402-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03402-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Faria NR, Claro IM, Candido D, et al. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings
2021.  [cited 2021 February15]. Available from: https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586</Citation></Reference><Reference><Citation>PANGO lineages . B.1.1.7 report
2021.  [cited 2021 February15]. Available from: https://cov-lineages.org/global_report_B.1.1.7.html</Citation></Reference><Reference><Citation>Volz E, Mishra S, Chand M, et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: insights from linking epidemiological and genetic data. medRxiv. 2021. DOI:10.1101/2020.12.30.20249034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.30.20249034</ArticleId></ArticleIdList></Reference><Reference><Citation>PANGO lineages . B.1.351 report
2021.  [cited 2021 February15]. Available from: https://cov-lineages.org/global_report_B.1.351.html</Citation></Reference><Reference><Citation>PANGO lineages . P.1 report
2021.  [cited 2021 February15]. Available from: https://cov-lineages.org/global_report_P.1.html</Citation></Reference><Reference><Citation>CGTN . Guangdong detects first COVID-19 case of variant found in S. Africa
2021.  [cited 2021 February15]. Available from: https://news.cgtn.com/news/2021-01-06/Guangdong-detects-first-COVID-19-case-of-variant-found-in-S-Africa-WPW5sbHcju/index.html</Citation></Reference><Reference><Citation>Chen H, Huang X, Zhao X. et al. Notes from the field: the first case of new variant COVID-19 originating in the United Kingdom detected in a returning student &#x2014; shanghai Municipality, China, December 14, 2020. China CDC Weekly. 2021;3(1):1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8393080</ArticleId><ArticleId IdType="pubmed">34594844</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccoli L, Park Y-J, Tortorici MA, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020;183(4):1024&#x2013;1042.e21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7494283</ArticleId><ArticleId IdType="pubmed">32991844</ArticleId></ArticleIdList></Reference><Reference><Citation>McCallum M, Marco AD, Lempp F, et al. N-terminal domain antigenic mapping reveals a site of vulnerability for sars-cov-2. bioRxiv. 2021. DOI:10.1101/2021.01.14.426475</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.14.426475</ArticleId><ArticleId IdType="pmc">PMC7962585</ArticleId><ArticleId IdType="pubmed">33761326</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerutti G, Guo Y, Zhou T, et al. Potent sars-cov-2 neutralizing antibodies directed against spike n-terminal domain target a single supersite. bioRxiv. 2021. DOI:10.1101/2021.01.10.426120</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.10.426120</ArticleId><ArticleId IdType="pmc">PMC7953435</ArticleId><ArticleId IdType="pubmed">33789084</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes CO, Jette CA, Abernathy ME, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020;588(7839):682&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092461</ArticleId><ArticleId IdType="pubmed">33045718</ArticleId></ArticleIdList></Reference><Reference><Citation>Cele S, Gazy I, Jackson L, et al. Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma. Public Health. 2021. DOI:10.1101/2021.01.26.21250224</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.26.21250224</ArticleId><ArticleId IdType="pmc">PMC9867906</ArticleId><ArticleId IdType="pubmed">33780970</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. bioRxiv. 2021. DOI:10.1038/s41586-021-03398-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03398-2</ArticleId><ArticleId IdType="pubmed">33684923</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran WF, Lam EC, Denis KS, et al. Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. medRxiv. 2021. DOI:10.1101/2021.02.14.21251704</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.14.21251704</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou YJ, Chiba S, Halfmann P, et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science. 2020;370(6523):1464&#x2013;1468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7775736</ArticleId><ArticleId IdType="pubmed">33184236</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniloski Z, Jordan TX, Ilmain JK, et al. The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types. eLife. 2021;10. DOI:10.7554/eLife.65365</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.65365</ArticleId><ArticleId IdType="pmc">PMC7891930</ArticleId><ArticleId IdType="pubmed">33570490</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozono S, Zhang Y, Ode H, et al. SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity. Nat Commun. 2021;12(1):1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7870668</ArticleId><ArticleId IdType="pubmed">33558493</ArticleId></ArticleIdList></Reference><Reference><Citation>Plante JA, Liu Y, Liu J, et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2020. DOI:10.1038/s41586-020-2895-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2895-3</ArticleId><ArticleId IdType="pmc">PMC8158177</ArticleId><ArticleId IdType="pubmed">33106671</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Teodoro G, Valleriani F, Puglia I, et al. SARS-CoV-2 replicates in respiratory ex vivo organ cultures of domestic ruminant species. Vet Microbiol. 2021;252:108933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7685048</ArticleId><ArticleId IdType="pubmed">33278734</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo-Redondo R, Nam HH, Roberts SC, et al. A unique clade of SARS-CoV-2 viruses is associated with lower viral loads in patient upper airways. medRxiv. 2020. DOI:10.1101/2020.05.19.20107144</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.05.19.20107144</ArticleId><ArticleId IdType="pmc">PMC7655495</ArticleId><ArticleId IdType="pubmed">33186810</ArticleId></ArticleIdList></Reference><Reference><Citation>Muruato AE, Fontes-Garfias CR, Ren P, et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat Commun. 2020;11(1):4059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7426916</ArticleId><ArticleId IdType="pubmed">32792628</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissman D, Alameh M-G, De Silva T, et al. D614G spike mutation increases SARS CoV-2 susceptibility to neutralization. Cell Host Microbe. 2021;29(1):23&#x2013;31.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7707640</ArticleId><ArticleId IdType="pubmed">33306985</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomson EC, Rosen LE, Shepherd JG, et al. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell. 2021;184(5):1171&#x2013;1187.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7843029</ArticleId><ArticleId IdType="pubmed">33621484</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health England . Investigation of novel SARS-CoV-2 variant: variant of concern 202012/01. 2020. &#xa0;[cited 2021&#xa0;Feb&#xa0;15]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959360/Variant_of_Concern_VOC_202012_01_Technical_Briefing_3.pdf</Citation></Reference><Reference><Citation>O&#x2019;Toole A, Hill V, Pybus OG, et al. Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2
2021.  [cited 2021 March6]. Available from: https://virological.org/t/tracking-the-international-spread-of-sars-cov-2-lineages-b-1-1-7-and-b-1-351-501y-v2/592</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8176267</ArticleId><ArticleId IdType="pubmed">34095513</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Nair MS, Liu L, et al. Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization. bioRxiv. 2021. DOI:10.1101/2021.01.25.428137</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.25.428137</ArticleId></ArticleIdList></Reference><Reference><Citation>Bal A, Destras G, Gaymard A, et al. Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69&#x2013;V70, France, August to December 2020. Eurosurveillance. 2021;26(3):3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7848679</ArticleId><ArticleId IdType="pubmed">33478625</ArticleId></ArticleIdList></Reference><Reference><Citation>Group NaERVTA . Meeting on SARS-CoV-2 variant under investigation VUI-202012/01. 2020.  [cited 2021 February15]. Available from: https://khub.net/documents/135939561/338928724/SARS-CoV-2&#xb1;variant&#xb1;under&#xb1;investigation%2C&#xb1;meeting&#xb1;minutes.pdf/962e866b-161f-2fd5-1030-32b6ab467896?t=1608470511452</Citation></Reference><Reference><Citation>Shen X, Tang H, Mcdanal C, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Social Science Electronic Publishing; 2021. Available from:https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3777473</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7934674</ArticleId><ArticleId IdType="pubmed">33705729</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier DA, Marco AD, Ferreira IATM, et al. Impact of SARS-CoV-2 B.1.1.7 spike variant on neutralisation potency of sera from individuals vaccinated with Pfizer vaccine BNT162b2. medRxiv. 2021. DOI:10.1101/2021.01.19.21249840</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.19.21249840</ArticleId></ArticleIdList></Reference><Reference><Citation>Muik A, Wallisch A-K, S&#xe4;nger B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine&#x2013;elicited human sera. Science. 2021;371(6534):eabg6105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7971771</ArticleId><ArticleId IdType="pubmed">33514629</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerutti G, Guo Y, Zhou T, et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Virology. 2021. DOI:10.1101/2021.01.10.426120</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.10.426120</ArticleId><ArticleId IdType="pmc">PMC7953435</ArticleId><ArticleId IdType="pubmed">33789084</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaney AJ, Starr TN, Gilchuk P, et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe. 2020;29(1):44&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7676316</ArticleId><ArticleId IdType="pubmed">33259788</ArticleId></ArticleIdList></Reference><Reference><Citation>Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369(6506):1014&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299283</ArticleId><ArticleId IdType="pubmed">32540904</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaney AJ, Starr TN, Gilchuk P, et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe. 2021;29(1):44&#x2013;57.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7676316</ArticleId><ArticleId IdType="pubmed">33259788</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Zheng H, Lin H, et al. Identification of common deletions in the spike protein of severe acute respiratory syndrome coronavirus 2. J Virol. 2020;94(17):17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7431800</ArticleId><ArticleId IdType="pubmed">32571797</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife. 2020;9. DOI:10.7554/eLife.61312</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.61312</ArticleId><ArticleId IdType="pmc">PMC7723407</ArticleId><ArticleId IdType="pubmed">33112236</ArticleId></ArticleIdList></Reference><Reference><Citation>Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021. DOI:10.1101/2021.01.18.427166</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.18.427166</ArticleId><ArticleId IdType="pubmed">33654292</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson &amp; Johnson . Johnson &amp; Johnson announces single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of its Phase 3 ENSEMBLE trial
2021.  [cited 2021 February15]. Available from: https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial</Citation></Reference><Reference><Citation>Witwatersrand U
Oxford Covid-19 vaccine trial results
2021.  [cited 2021 February15]. Available from: https://www.wits.ac.za/covid19/covid19-news/latest/oxford-covid-19-vaccine-trial-results.html</Citation></Reference><Reference><Citation>Novavax . Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK Phase 3 trial
2021.  [cited 2021 February15]. Available from: https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3</Citation></Reference><Reference><Citation>Vaccine KK
2.0: moderna and other companies plan tweaks that would protect against new coronavirus mutations
2021.  [cited 2021 February15]. Available from: https://www.sciencemag.org/news/2021/01/vaccine-20-moderna-and-other-companies-plan-tweaks-would-protect-against-new</Citation></Reference><Reference><Citation>PANGO lineages . A.23.1 report
2021.  [cited 2021 February15]. Available from: https://cov-lineages.org/global_report_A.23.1.html</Citation></Reference><Reference><Citation>PANGO lineages . B.1.525 report
2021.  [cited 2021 February15]. Available from: https://cov-lineages.org/global_report_B.1.525.html</Citation></Reference><Reference><Citation>Lule BD, Phan MVT, Ssewanyana I, et al. A SARS-CoV-2 lineage A variant (A.23.1) with altered spike has emerged and is dominating the current Uganda epidemic. medRxiv. 2021. DOI:10.1101/2021.02.08.21251393</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.08.21251393</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Davis BD, Chen SS, et al. Emergence of a novel SARS-CoV-2 variant in southern California. JAMA. 2021. DOI:10.1101/2021.01.18.21249786</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.18.21249786</ArticleId><ArticleId IdType="pmc">PMC7879386</ArticleId><ArticleId IdType="pubmed">33571356</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones BE, Brown-Augsburger PL, Corbett KS, et al. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. bioRxiv. 2020. DOI:10.1101/2020.09.30.318972</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.30.318972</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreano E, Piccini G, Licastro D, et al. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv. 2020. DOI:10.1101/2020.12.28.424451</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.28.424451</ArticleId><ArticleId IdType="pmc">PMC8433494</ArticleId><ArticleId IdType="pubmed">34417349</ArticleId></ArticleIdList></Reference><Reference><Citation>Supasa P, Zhou D, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell. 2021. DOI:10.1016/j.cell.2021.02.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.02.033</ArticleId><ArticleId IdType="pmc">PMC7891044</ArticleId><ArticleId IdType="pubmed">33743891</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera. Cell. 2021. DOI:10.1016/j.cell.2021.02.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.02.037</ArticleId><ArticleId IdType="pmc">PMC7901269</ArticleId><ArticleId IdType="pubmed">33730597</ArticleId></ArticleIdList></Reference><Reference><Citation>Jangra S, Ye C, Rathnasinghe R, et al. The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera. medRxiv. 2021. DOI:10.1101/2021.01.26.21250543</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.26.21250543</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathnasinghe R, Jangra S, Cupic A, et al. The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera. medRxiv. 2021. DOI:10.1101/2021.01.19.21249592</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.19.21249592</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie X, Liu Y, Liu J, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med. 2021. DOI:10.1038/s41591-021-01270-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01270-4</ArticleId><ArticleId IdType="pubmed">33558724</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie X, Zou J, Fontes-Garfias CR, et al. Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. bioRxiv. 2021. DOI:10.1101/2021.01.07.425740</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.07.425740</ArticleId><ArticleId IdType="pubmed">33558724</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K, Werner AP, Moliva JI, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv. 2021. DOI:10.1101/2021.01.25.427948</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.25.427948</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang B, Dai L, Wang H, et al. Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines. bioRxiv. 2021. DOI:10.1101/2021.02.01.429069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.01.429069</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxford University . Oxford vaccine effective against major B.1.1.7 &#x2018;Kent&#x2019; coronavirus strain circulating in the UK
2021.  [cited 2021 February15]. Available from: https://www.research.ox.ac.uk/Article/2021-02-05-oxford-vaccine-effective-against-major-b-1-1-7-kent-coronavirus-strain-circulating-in-the-uk</Citation></Reference><Reference><Citation>Oxford University . ChAdOx1 nCov-19 provides minimal protection against mild-moderate COVID-19 infection from B.1.351 coronavirus variant in young South African adults
2021.  [cited 2021 February15]. Available from: https://www.research.ox.ac.uk/Article/2021-02-07-chadox1-ncov-19-minimal-protection-against-mild-covid-19-from-b-1-351-variant-in-young-sa-adults</Citation></Reference><Reference><Citation>Janet Woodcock MD
Coronavirus (COVID-19) Update: FDA continues important work to support medical product development to address new virus variants
2021.  [cited 2021 February15]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-important-work-support-medical-product-development-address</Citation></Reference><Reference><Citation>CNN . Moderna expects vaccine will be protective against variants, but will test boosters to improve immunity. 2021.  [cited 2021 February15]. Available from: https://www.wktv.com/content/news/573657962.html</Citation></Reference><Reference><Citation>Sputnik . The Russian direct investment fund is willing to start combined clinical trials of the Sputnik V and AstraZeneca vaccine in Ukraine
2021.  [cited 2021 February15]. Available from: http://sputniknews.cn/covid-2019/202101031032825830/</Citation></Reference><Reference><Citation>Oxford University . Oxford leads first trial investigating dosing with alternating vaccines
2021.  [cited 2021 February15]. Available from: https://www.research.ox.ac.uk/Article/2021-02-04-oxford-leads-first-trial-investigating-dosing-with-alternating-vaccines</Citation></Reference><Reference><Citation>Public Health England . COVID-19 vaccination programme Information for healthcare practitioners
2021.  [cited 2021 February15]; Version 3.3 [Available from:
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/960977/COVID-19_vaccination_programme_guidance_for_healthcare_workers_11_February_2021_v3.3.pdf</Citation></Reference><Reference><Citation>Stephen M, Hahn MD. FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines
2021.  [cited 2021 February15]. Available from: https://www.fda.gov/news-events/press-announcements/fda-statement-following-authorized-dosing-schedules-covid-19-vaccines</Citation></Reference><Reference><Citation>Businesswire . Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa
2021.  [cited 2021 February15]. Available from: https://www.businesswire.com/news/home/20210125005439/en</Citation></Reference><Reference><Citation>GlaxoSmithKline. GSK and CureVac to develop next generation mRNA COVID-19 vaccines
2021.  [cited 2021 February15]. Available from: https://www.gsk.com/en-gb/media/press-releases/gsk-and-curevac-to-develop-next-generation-mrna-covid-19-vaccines/</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>